I. L. Gade, S. Braekkan, I. A. Naess, J. Hansen, F. Rosendaal et al., Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort, Thromb Res, vol.158, pp.157-60, 2017.

G. Gatta, L. Botta, S. Rossi, T. Aareleid, M. Bielska-lasota et al., Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study, Lancet Oncol, vol.15, issue.1, pp.35-47, 2014.

C. Pui, J. J. Yang, S. P. Hunger, R. Pieters, M. Schrappe et al., Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration, J Clin Oncol, vol.33, issue.27, pp.2938-2986, 2015.

U. H. Athale and A. Chan, Thrombosis in children with acute lymphoblastic leukemia

, Thromb Res, vol.111, issue.3, pp.125-156, 2003.

V. Caruso, Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients, Blood, vol.108, issue.7, pp.2216-2238, 2006.

L. B. Silverman, Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01, Blood, vol.97, issue.5, pp.1211-1219, 2001.

N. Hijiya and I. M. Van-der-sluis, Asparaginase-associated toxicity in children with acute lymphoblastic leukemia, Leuk Lymphoma, vol.57, issue.4, pp.748-57, 2016.

K. M. Ghanem, R. M. Dhayni, C. Al-aridi, N. Tarek, H. Tamim et al., Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatr Blood Cancer, vol.64, p.26694, 2017.

U. Athale, S. Siciliano, L. Thabane, N. Pai, S. Cox et al., Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer, Pediatr Blood Cancer, vol.51, issue.6, pp.792-799, 2008.

L. G. Mitchell and . Group, A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer, vol.97, pp.508-524, 2003.

L. Mitchell, M. Lambers, S. Flege, G. Kenet, V. Li-thiao-te et al., Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study, Blood, vol.115, issue.24, pp.4999-5004, 2010.

J. H. Payne and A. J. Vora, Thrombosis and acute lymphoblastic leukaemia, Br J Haematol

U. H. Athale, C. Laverdiere, T. Nayiager, Y. Delva, G. Foster et al.,

, Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study. BMC Cancer, vol.17, 2017.

U. Nowak-göttl, E. Ahlke, G. Fleischhack, D. Schwabe, R. Schobess et al.,

, Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration, Blood, vol.101, issue.7, pp.2529-2562, 2003.

D. Harlev, I. Zaidman, G. Sarig, W. Ben-arush, M. Brenner et al., Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment, 16. Levy-Mendelovich S, vol.126, issue.2, pp.94-101, 2010.

I. Klaassen, M. N. Lauw, M. Fiocco, I. M. Van-der-sluis, R. Pieters et al.,

, Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis, Res Pract Thromb Haemost, vol.3, issue.2, pp.234-275, 2019.

I. Klaassen, C. Zuurbier, B. Hutten, C. Van-den-bos, A. Schouten et al.,

, Venous Thrombosis in Children with Acute Lymphoblastic Leukemia Treated on DCOG ALL-9 and ALL-10 Protocols: The Effect of Fresh Frozen Plasma. TH Open, pp.109-125, 2019.

C. U. Rank, N. Toft, R. Tuckuviene, K. Grell, O. J. Nielsen et al.,

, Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood, vol.131, pp.2475-84, 2018.

J. Greiner, M. Schrappe, A. Claviez, M. Zimmermann, C. Niemeyer et al.,

, THROMBOTECT -a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents, Haematologica, 2019.

C. Protocol and . Pdf,

P. Massicotte, J. A. Julian, M. Gent, K. Shields, V. Marzinotto et al., An openlabel randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial, Thromb Res, vol.109, issue.2-3, pp.101-109, 2003.

I. Klaassen, M. N. Lauw, M. D. Van-de-wetering, and B. J. Biemond,

. Fch, TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial, BMC Pediatr, vol.17, issue.1, 2017.

S. O'brien, D. Li, L. Mitchell, T. Hess, P. Zee et al., PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design, Thromb Haemost, 2019.

M. N. Levine, C. Gu, H. A. Liebman, C. P. Escalante, S. Solymoss et al., A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer, J Thromb Haemost, vol.10, issue.5, pp.807-821, 2012.

U. Nowak-göttl, B. Rath, M. Binder, J. Hassel, J. Wolff et al., Innefficacity of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy

M. N. Lauw, B. Van-der-holt, S. Middeldorp, J. Meijers, J. J. Cornelissen et al.,

, Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation, Thromb Haemost, vol.109, issue.4, pp.633-675, 2013.

L. Mitchell, M. Andrew, K. Hanna, T. Abshire, J. Halton et al., Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving lasparaginase for acute lymphoblastic leukemia: Results of the PARKAA study, Thromb Haemost, vol.90, issue.08, pp.235-279, 2003.

M. Hunault-berger, P. Chevallier, M. Delain, C. Bulabois, S. Bologna et al.,

, Changes in antithrombin and fibrinogen levels during induction chemotherapy with Lasparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study

, Haematologica, vol.93, issue.10, pp.1488-94, 2008.

G. Sebire, Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome, Brain, vol.128, issue.3, pp.477-89, 2005.

J. H. Payne and A. J. Vora, Thrombosis and acute lymphoblastic leukaemia, Br J Haematol

A. Lebas, S. Chabrier, M. Tardieu, and M. Kossorotoff, Traitement anticoagulant des thromboses veineuses cérébrales de l'enfant et du nouveau-né. Les recommandations de la Société française de neurologie pédiatrique (SFNP). Arch Pédiatrie, vol.18, pp.446-58, 2011.

P. Monagle, A. Chan, N. A. Goldenberg, R. N. Ichord, J. M. Journeycake et al., Antithrombotic Therapy in Neonates and Children, Chest, vol.141, issue.2, pp.737-801, 2012.

A. Qureshi, C. Mitchell, S. Richards, A. Vora, and N. Goulden, Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe, Br J Haematol, vol.149, issue.3, pp.410-413, 2010.

, VII. ANNEXES Annexe, vol.1